A PHASE 2B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF AGN 151607 DP (USAN: GEMIBOTULINUMTOXINA) FOR THE TREATMENT OF UPPER LIMB ESSENTIAL TREMOR IN ADULTS

Registry ID

M25-850

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ABBVIE CORPORATION

Start date

2026-07-23

Last update

2026-06-18

Conditions

• ESSENTIAL TREMOR

Related clinical trials

• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGE FINDING CLINICAL TRIAL TO EVALUATE THE TOLERABILITY, SAFETY, AND EFFICACY OF PRAX-944 IN THE TREATMENT OF ADULTS WITH ESSENTIAL TREMOR
• USE OF KINEMATIC ASSESSMENT OF HAND TREMOR PRE- AND POST-TREATMENT WITH BOTULINUM TOXIN TYPE A IN ESSENTIAL TREMOR AND PARKINSON DISEASE

View on source registry